New hope for older MDS patients: oral drug trial launches
NCT ID NCT07616336
First seen Jun 11, 2026 · Last updated Jun 11, 2026
Summary
This study tests an oral drug called chidamide in 15 people aged 60 or older with intermediate-to-high-risk myelodysplastic syndromes (MDS), a bone marrow disorder that can lead to leukemia. The goal is to see if chidamide can improve blood cell counts and control the disease with manageable side effects. Participants will take the drug twice weekly and be monitored for response and safety.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROMES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Zhongshan Hospital (Xiamen), Fudan University
Xiamen, Fujian, 361015, China
Conditions
Explore the condition pages connected to this study.
Conditions inferred from the trial description
These were inferred from the trial's summary, not listed by the trial registrant.